Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity

Lupus

Volumn 6, Issue 5, 1997, Pages 425-435

  Villarreal, G M ^a   Drenkard, C ^a   Villa, A R ^b   Slor, H ^c   Shafrir, S ^c   Bakimer, R ^d   Shoenfeld, Y ^d   Alarcon Segovia D ^a,b  

^a Inst Natl de la Nutrición   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c TEL AVIV UNIVERSITY   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoantibodies; Disease activity; Idiotypes; Prevalence; Remission; Systemic lupus erythematosus

Indexed keywords

DNA ANTIBODY; HISTONE ANTIBODY; MITOCHONDRION ANTIBODY; SINGLE STRANDED DNA;

ADULT; ANTIBODY TITER; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030826584     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600503     Document Type: Article

References (44)

1. Shoenfeld Y et al. The role of human anti-DNA idiotype 16/6 in autouimmunity. Clin Immunol Immunopathol 1989; 51: 313-325.
2. Bakimer R et al. The frequency of a common anti-DNA antibody idiotype (16/6) in different populations of patients with systemic lupus erythematosus. J Rheumatol 1991; 18: 1035-1037.
3. Gripenberg M, Teppo AM, Friman C Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus. Rheumatol Int 1991; 11: 209-213.
4. Borg A et al. Changes in levels of antibodies against the 70kDa and polypeptides of the U1RNP complex in relation to exacerbations of systemic lupus erythematosus. J Rheumatol 1991; 18: 363-367.
5. Muller S et al. Longitudinal analysis of antibodies to histones, Sm-D peptides and ubiquitm in the serum of patients with systemic lupus erythematosus, rheumatoid arthritis and tuberculosis. Clin Exp Rheumatol 1990; 8: 445-453.
6. Purcell SM, Lieu TS, Davis BM, Sontheimer RD. Relationship between circulating anti-Ro/SSA antibody (a-Ro) levels and skin disease activity in subacute cutaneous lupus erythematosus (SCLE) Arthritis Rheum 1985; 28: S76 (abstract D4).
7. Blanco F, Kalsi J, Isenberg DA. Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases. Clin Exp Immunol 1991; 86: 66-70.
8. Simmons-O'Brien E et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine 1995; 74: 109-130.
9. Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus 1993; 2: 15-19.
10. Skinner RP, Maddison PJ. Analysis of polyethylene glycol precipitates from SLE sera: antibody enrichment in association with disease activity. Clin Exp Rheumatol 1990; 8: 553-560.
11. Smolen JS, Hassfeld W, Graninger W, Steiner G. Antibodies to antinuclear subsets in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol 1990; 8: 41-4.
12. Pérez-Vázquez ME, Cabiedes J, Cabral AR, Alarcón-Segovia D. Decrease in serum antiphospholipid antibody levels upon development of nephrotic syndrome in patients with systemic lupus erythematosus: relationship to urinary loss of IgG and other factors. Am J Med 1992, 92: 357-362.
13. Nossent JC et al. Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int 1991; 11: 77-82.
14. Hietarinta M, Viander M, Toivanen A, Lassila O. Clinical significance of autoantibodies in systemic lupus erythematosus. Br J Rheumatol 1994; 33: 1202-1203.
15. Shoenfeld Y, Mozes E. Pathogenic anti-DNA idiotype (16/6 Id) in systemic lupus erythematosus. Rheumatol Int 1991; 11: 91-93.
16. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
17. Drenkard C et al. Remission of systemic lupus erythematosus, Medicine 1996; 75: 88-98.
18. Shoenfeld Y et al. Polyspecificity of monoclonal lupus autoantibodies by human hybridoma. N Engl J Med 1983; 308: 414-420.
19. Shoenfeld Y, El-Roeiy A, Ben-Yehuda O, Pick AL. Detection of anti-histone activity in the sera of patients with monoclonal gammopathies. Clin Immunol Immunopathol 1987; 42: 250-258.
20. Shoenfeld Y et al. Monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol 1986; 66: 255-261.
21. Isenberg DA, Shoenfeld Y, Schwartz RS. Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum 1984; 27: 132-138.
22. Firer M, Shoenfeld Y, Isenberg DA, Slor H. The use of ELISA for the measurement of autoantibodies to nuclear antigens: comparison with other methodologies. Isr J Med Sci 1988; 24: 747-751.
23. Zurgil N et al. Antimithochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol 1992; 12: 201-209.
24. Isenberg D et al. Anti-DNA antibody idiotypes in SLE. Lancet 1984; ii: 417-421.
25. Shoenfeld Y, Mozes E. Pathogenic idiotypes of autoantibodies and autoimmunity: a lesson from a new syndrome of experimental SLE. FASEB J 1990; 4: 2646-2651.
26. Cupples LA et al. Multiple testing of hypotheses in comparing two groups. Ann Int Med 1984; 100: 122-129.
27. Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley and Sons: New York, 1989, p 25.
28. Kleinbaum DG, Kupper LL Applied Regression Analysis and Other Multivariable Methods. Duxbury Press: Massachusetts, 1978, p. 414.
29. Guzmán J et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
30. Arce-Salinas A, Cardiel MH, Guzmán J, Alcocer-Varela J. Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 1996; 23: 846-849.
31. Walz LeBlanc BAE, Urowitz MB, Gladman DD. Serological active, clinically quiescent systemic lupus erythematosus - longterm follow-up. J Rheumatol 1994; 21: 174-175 (letter).
32. Froelich CJ, Wallman J, Skosey JL, Teodorescu M. Clinical value of an integrated ELISA system for the detection of 6 autoantibodies (ssDNA, dsDNA, Sm, RNP/Sm, SSA, and SSB). J Rheumatol 1990; 17: 192-200.
33. Harley J et al. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum 1989; 32: 826-836.
34. Swaak AJG, Huysen V, Nossent JC, Smeenk RJT. Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin Rheumatol 1990; 9: 82-95.
35. Meroni PL et al. Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity. Clin Exp Immunol 1987; 67: 484-491.
36. Drenkard C, Sánchez-Guerrero J, Alarcón-Segovia D Fall in antiphospholipid antibody at the time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol 1989; 16: 614-617.
37. 2-glycoprotein-1 than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
38. 2 glycoprotein 1 antibodies in the antiphospholipid syndrome. J Rheumatol 1994; 21: 1678-1683.
39. Delezé M, Oria C, Alarcón-Segovia D. Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus Relationship to antiphospholipid antibodies. J Rheumatol 1989; 16: 614-617.
40. Hochberg MC et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985; 64: 285-295.
41. García-de la Torre I, Sánchez-Guerrero S, Salmón-de la Torre G, Hemández-Vázquez L. Prevalence of anti-SSA (Ro) antibodies in a Mexican population of patients with various systemic rheumatic diseases. J Rheumatol 1987; 14: 479-481.
42. Gripenberg M, Teppo AM, Friman C. Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus. Rheumatol Int 1991; 11: 209-213.
43. Alarcón-Segovia D. The pathogenesis of immune dysregulation in systemic lupus erythematosus. A troika. J Rheumatol 1984; 11: 588-590.
44. Llorente L et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-844.